Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration

Lena Rung,1 Monica Lövestam-Adrian21Department of Ophthalmology, Helsingborg Hospital, Helsingborg, 2Department of Ophthalmology, Lund University, Skåne University Hospital, Malmö, SwedenBackground: The purpose of this study was to evaluate the visual outcome...

Full description

Bibliographic Details
Main Authors: Rung L, Lövestam-Adrian M
Format: Article
Language:English
Published: Dove Medical Press 2013-02-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/three-year-follow-up-of-visual-outcome-and-quality-of-life-in-patients-a12309
id doaj-79aca22bb5204b1db10fa4db528d364a
record_format Article
spelling doaj-79aca22bb5204b1db10fa4db528d364a2020-11-24T23:39:03ZengDove Medical PressClinical Ophthalmology1177-54671177-54832013-02-012013default395401Three-year follow-up of visual outcome and quality of life in patients with age-related macular degenerationRung LLövestam-Adrian MLena Rung,1 Monica Lövestam-Adrian21Department of Ophthalmology, Helsingborg Hospital, Helsingborg, 2Department of Ophthalmology, Lund University, Skåne University Hospital, Malmö, SwedenBackground: The purpose of this study was to evaluate the visual outcome and self-reported vision-targeted health status in patients treated with intravitreal ranibizumab for wet age-related macular degeneration (AMD).Methods: A total of 51 eyes from 50 patients aged 76 ± 7 years, with wet AMD not previously treated, were included in this prospective study. Best corrected visual acuity was examined using Early Treatment Diabetic Research Study charts and near vision reading. All patients underwent an ophthalmological examination, including fluorescein and indocyanine green angiography (occult cases) and optical coherence tomography. The Visual Function Questionnaire test was completed before and 37 ± 7 months after the start of intravitreal injections.Results: The patients received a mean number of 7.8 ± 5.0 (range 2–22) injections. One month after the third intravitreal injection, significant improvement was seen in both visual acuity (53 ± 14 to 61 ± 14 letter, P = 0.001) and near vision (17 ± 9 to 11 ± 8 points, P = 0.001). During follow-up, mean visual acuity decreased from 53 ± 14 to 44 ± 24 letters (P = 0.011), and near vision decreased from 17 ± 9 to 20 ± 11 points (P = 0.048). Despite visual impairment, the quality of life test revealed no significant decrease in mental health (P = 0.529) or ability to read a newspaper (P = 0.21), but a decrease in distance activities (reading street signs, steps, going to the theater) from 57 ± 27 to 46 ± 31 points (P = 0.007) was documented.Conclusion: Decreased visual acuity was related to a decrease in self-reported visual function for distance activities, while mental health items, such as worrying, were not influenced.Keywords: visual outcome, quality of life, age-related macular degenerationhttp://www.dovepress.com/three-year-follow-up-of-visual-outcome-and-quality-of-life-in-patients-a12309
collection DOAJ
language English
format Article
sources DOAJ
author Rung L
Lövestam-Adrian M
spellingShingle Rung L
Lövestam-Adrian M
Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
Clinical Ophthalmology
author_facet Rung L
Lövestam-Adrian M
author_sort Rung L
title Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
title_short Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
title_full Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
title_fullStr Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
title_full_unstemmed Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
title_sort three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5467
1177-5483
publishDate 2013-02-01
description Lena Rung,1 Monica Lövestam-Adrian21Department of Ophthalmology, Helsingborg Hospital, Helsingborg, 2Department of Ophthalmology, Lund University, Skåne University Hospital, Malmö, SwedenBackground: The purpose of this study was to evaluate the visual outcome and self-reported vision-targeted health status in patients treated with intravitreal ranibizumab for wet age-related macular degeneration (AMD).Methods: A total of 51 eyes from 50 patients aged 76 ± 7 years, with wet AMD not previously treated, were included in this prospective study. Best corrected visual acuity was examined using Early Treatment Diabetic Research Study charts and near vision reading. All patients underwent an ophthalmological examination, including fluorescein and indocyanine green angiography (occult cases) and optical coherence tomography. The Visual Function Questionnaire test was completed before and 37 ± 7 months after the start of intravitreal injections.Results: The patients received a mean number of 7.8 ± 5.0 (range 2–22) injections. One month after the third intravitreal injection, significant improvement was seen in both visual acuity (53 ± 14 to 61 ± 14 letter, P = 0.001) and near vision (17 ± 9 to 11 ± 8 points, P = 0.001). During follow-up, mean visual acuity decreased from 53 ± 14 to 44 ± 24 letters (P = 0.011), and near vision decreased from 17 ± 9 to 20 ± 11 points (P = 0.048). Despite visual impairment, the quality of life test revealed no significant decrease in mental health (P = 0.529) or ability to read a newspaper (P = 0.21), but a decrease in distance activities (reading street signs, steps, going to the theater) from 57 ± 27 to 46 ± 31 points (P = 0.007) was documented.Conclusion: Decreased visual acuity was related to a decrease in self-reported visual function for distance activities, while mental health items, such as worrying, were not influenced.Keywords: visual outcome, quality of life, age-related macular degeneration
url http://www.dovepress.com/three-year-follow-up-of-visual-outcome-and-quality-of-life-in-patients-a12309
work_keys_str_mv AT rungl threeyearfollowupofvisualoutcomeandqualityoflifeinpatientswithagerelatedmaculardegeneration
AT lampoumlvestamadrianm threeyearfollowupofvisualoutcomeandqualityoflifeinpatientswithagerelatedmaculardegeneration
_version_ 1725514808104583168